Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?
作者信息
De Mello Ramon Andrade, Zhu Jin-Hui, Iavelberg Jairo, Potim Artur Henrique, Simonetti Débora, Silva José Antônio, Castelo-Branco Pedro, Pozza Daniel Humberto, Tajima Carla Chizuru, Tolia Maria, Antoniou Georgio
机构信息
Post-graduation Program in Medicine, Precision Oncology & Health Economics Research Group (OncoPRECH), Faculty of Medicine, Nine of July University (UNINOVE), São Paulo, Brazil.
Division of Medical Oncology/Oncotorax Group, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
出版信息
Transl Lung Cancer Res. 2020 Dec;9(6):2311-2314. doi: 10.21037/tlcr-20-625.
Abstract
摘要
相似文献
1
Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?TIM-3作为非小细胞肺癌生物标志物或潜在靶点的现状与未来展望：其在临床实践中是否具有作用？
Transl Lung Cancer Res. 2020 Dec;9(6):2311-2314. doi: 10.21037/tlcr-20-625.
2
TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner.TIM-4以依赖RGD基序的方式促进非小细胞肺癌的生长。
Br J Cancer. 2015 Nov 17;113(10):1484-92. doi: 10.1038/bjc.2015.323. Epub 2015 Oct 29.
3
Prognostic value of TIM-1 expression in human non-small-cell lung cancer.TIM-1 表达在人非小细胞肺癌中的预后价值。
J Transl Med. 2019 May 28;17(1):178. doi: 10.1186/s12967-019-1931-2.
4
TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival.TIMELESS 在肺癌中过表达，其表达与患者预后不良相关。
Cancer Sci. 2013 Feb;104(2):171-7. doi: 10.1111/cas.12068. Epub 2013 Jan 7.
5
Comprehensive Analysis of the Expression, Relationship to Immune Infiltration and Prognosis of TIM-1 in Cancer.癌症中TIM-1的表达、与免疫浸润的关系及预后的综合分析
Front Oncol. 2020 Sep 4;10:1086. doi: 10.3389/fonc.2020.01086. eCollection 2020.
6
The expression of the circadian gene TIMELESS in non-small-cell lung cancer and its clinical significance.昼夜节律基因TIMELESS在非小细胞肺癌中的表达及其临床意义。
Int J Clin Exp Pathol. 2020 Sep 1;13(9):2297-2304. eCollection 2020.
7
IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB.白细胞介素-6 通过 NF-κB 上调 TIM-4 促进非小细胞肺癌转移。
Cell Prolif. 2020 Mar;53(3):e12776. doi: 10.1111/cpr.12776. Epub 2020 Feb 5.
8
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.TIM-3 表达特征性地存在于肿瘤组织中的调节性 T 细胞中，并且与肺癌进展相关。
PLoS One. 2012;7(2):e30676. doi: 10.1371/journal.pone.0030676. Epub 2012 Feb 17.
9
[Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].[CD4⁺肿瘤浸润淋巴细胞上TIM-3的上调预示人类非小细胞肺癌预后不良]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Jun;31(6):808-11.
10
Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.TIM-3 在肺癌中的异位表达：非小细胞肺癌患者的一个潜在独立预后因素。
Am J Clin Pathol. 2012 Jun;137(6):978-85. doi: 10.1309/AJCP9Q6OVLVSHTMY.
引用本文的文献
1
Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.IFN-γ+ T 细胞中 PD-1/Tim-3 表达升高与急性髓系白血病患者预后不良相关。
Cancer Biol Ther. 2023 Dec 31;24(1):2278229. doi: 10.1080/15384047.2023.2278229. Epub 2023 Nov 14.
2
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices.晚期非小细胞肺癌免疫治疗的进展：优化治疗顺序并确定最佳选择
Cancers (Basel). 2023 Sep 13;15(18):4547. doi: 10.3390/cancers15184547.
3
Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.用于单细胞分析的定量多重成像技术，以评估胸免疫肿瘤学中免疫治疗的预测标志物：前景与挑战。
Br J Cancer. 2023 Oct;129(9):1417-1431. doi: 10.1038/s41416-023-02318-7. Epub 2023 Jun 30.
4
Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer.循环 T 细胞激活和耗竭标志物与非小细胞肺癌的放射性肺炎及不良预后相关。
Front Immunol. 2022 Jul 14;13:875152. doi: 10.3389/fimmu.2022.875152. eCollection 2022.
5
Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.晚期无驱动基因突变非小细胞肺癌患者的免疫治疗及未来展望
Cancers (Basel). 2021 Dec 28;14(1):122. doi: 10.3390/cancers14010122.
本文引用的文献
1
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.布加替尼和阿来替尼用于治疗伴有或不伴有中枢神经系统转移的ALK重排阳性晚期非小细胞肺癌：一项系统评价和网状Meta分析
Cancers (Basel). 2020 Apr 10;12(4):942. doi: 10.3390/cancers12040942.
2
New insights into small-cell lung cancer development and therapy.小细胞肺癌发生发展与治疗的新认识。
Cell Biol Int. 2020 Aug;44(8):1564-1576. doi: 10.1002/cbin.11359. Epub 2020 Apr 18.
3
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.非小细胞肺癌中的T细胞免疫球蛋白和粘蛋白结构域包含分子3
Transl Lung Cancer Res. 2019 Dec;8(6):895-906. doi: 10.21037/tlcr.2019.11.17.
4
New emerging targets in cancer immunotherapy: the role of TIM3.癌症免疫治疗中的新兴靶点：TIM3的作用
ESMO Open. 2019 Jun 12;4(Suppl 3):e000497. doi: 10.1136/esmoopen-2019-000497. eCollection 2019.
5
New emerging targets in cancer immunotherapy: the role of LAG3.癌症免疫治疗中的新兴靶点：LAG3的作用
ESMO Open. 2019 Mar 12;4(2):e000482. doi: 10.1136/esmoopen-2018-000482. eCollection 2019.
6
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
7
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
8
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌的成本效果分析。
Lung Cancer. 2019 Apr;130:1-4. doi: 10.1016/j.lungcan.2019.01.019. Epub 2019 Feb 1.
9
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
10
Increased Tim-3 T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients.在纳武利尤单抗治疗期间，外周血单个核细胞（PBMCs）中 Tim-3 T 细胞的增加与晚期食管鳞癌患者的反应和预后相关。
Cancer Immunol Immunother. 2018 Nov;67(11):1673-1683. doi: 10.1007/s00262-018-2225-x. Epub 2018 Aug 20.
Zotero 插件